---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-026760"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2022-09-26T23:59:59+00:00"
generated_at: "2026-06-23T07:27:31.594088+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix completes dosing in Phase 1 trial of inhaled PUR3100 for acute migraine; data expected Q4 2022

## Summary
- All 26 healthy subjects completed dosing in double-blind, double-dummy Phase 1 trial of PUR3100 (inhaled DHE) vs IV DHE.
- Phase 1 safety, tolerability, and PK data expected in Q4 2022.
- PUR3100 uses iSPERSE dry-powder technology for self-administered inhaled delivery of dihydroergotamine.
- Migraine affects 38M in U.S.; 75% do not get relief from current prescription treatments.

## SEC filing metadata
- accession: 0001493152-22-026760
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2022-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315222026760/0001493152-22-026760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315222026760/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-026760
- JSON: https://secwatch.observer/filing/0001493152-22-026760.json
- Plain text: https://secwatch.observer/filing/0001493152-22-026760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.